Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0R2OU
|
||||
| Former ID |
DNCL001939
|
||||
| Drug Name |
Irdabisant
|
||||
| Synonyms |
CEP-26401
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Cognitive disorders [ICD9: 290-294, 294.0, 780.09, 780.9, 780.93; ICD10:F01-F07, F04, F05, R41.3] | Phase 1 | [1] | ||
| Company |
Cephalon
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C18H23N3O2
|
||||
| Canonical SMILES |
CC1CCCN1CCCOC2=CC=C(C=C2)C3=NNC(=O)C=C3
|
||||
| InChI |
1S/C18H23N3O2/c1-14-4-2-11-21(14)12-3-13-23-16-7-5-15(6-8-16)17-9-10-18(22)20-19-17/h5-10,14H,2-4,11-13H2,1H3,(H,20,22)/t14-/m1/s1
|
||||
| InChIKey |
XUKROCVZGZNGSI-CQSZACIVSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Histamine H3 receptor | Target Info | Antagonist | [2] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| Reactome | Histamine receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | Monoamine Transport | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01903824) Pharmacokinetics and Pharmacodynamics (PK/PD) of CEP-26401 in Healthy Subjects. U.S. National Institutes of Health. | ||||
| REF 2 | CEP-26401 (irdabisant), a potent and selective histamine H??receptor antagonist/inverse agonist with cognition-enhancing and wake-promoting activities. J Pharmacol Exp Ther. 2012 Jan;340(1):124-33. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.